CORT
NASDAQ · Pharmaceuticals
Corcept Therapeutics Inc
$110.29
-4.57 (-3.98%)
CORT News2 articles
Everpure Surges 2.2% After S&P 500 Inclusion, Adding $723M
Everpure (P) gains 2.2% after hours on S&P 500 promotion, adding $723M. Q2 revenue up 38% but free cash flow turns negative. Index inclusion effective Sept. 21.
Corcept Shares Leap 27% on Strong Lifyorli Launch and Upbeat Guidance
Corcept Therapeutics shares jumped 27.4% after Q2 revenue rose 32% to $256.1M, driven by Lifyorli sales of $47.6M. The company lifted its 2026 revenue outlook to $1.1-1.2 billion.